No of patients | 55 |
Age, median, years | 66.3 |
Range, years | 52–80 |
Characteristics | No of patients (%) |
TPSA (µg/L) | |
<4 | 17 (30.9) |
4–10 | 15 (27.3) |
10–20 | 7 (12.7) |
>20 | 16 (29.1) |
FPSA (µg/L) | |
0–1 | 31 (56.4) |
>1 | 24 (43.6) |
F/T | |
0–0.25 | 44 (80.0) |
0.25–1 | 9 (16.4) |
>1 | 2 (3.6) |
Gleason sum score | |
6 | 6 (10.9) |
7 | 21 (38.2) |
8 | 10 (18.2) |
9 | 17 (30.9) |
10 | 1 (1.82) |
Disease status | |
cT | |
T1 | 6 (10.9) |
T2a | 1 (1.82) |
T2b | 17 (30.9) |
T2c | 8 (14.5) |
T3a | 6 (10.9) |
T3b | 15 (27.3) |
T4 | 2 (3.64) |
N | |
N0 | 38 (69.1) |
N1 | 17 (30.9) |
M | |
M0 | 39 (70.9) |
M1 | 16 (29.1) |
Stage | |
I | 2 (3.64) |
IIA | 3 (5.45) |
IIB | 5 (9.09) |
IIC | 1 (1.82) |
IIIA | 6 (10.9) |
IIIB | 7 (12.7) |
IVA | 3 (5.45) |
IVB | 28 (50.9) |
Surgical margin status | |
Positive | 20 (36.4) |
Negative | 35 (63.6) |
cT, clinical T; FPSA, free prostate-specific antigen; TPSA, total prostate-specific antigen.